Causaly vs Tempus

Tempus has a disclosed valuation of $8.1B, while Causaly's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to Causaly's $66M — a gap of $984M. Combined, the two companies have completed 10 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Causaly sits at 45/100. That 39-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Causaly was founded by Elias Iosif in 2018. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Causaly: Causaly built a biomedical AI platform that extracts and maps causal relationships from scientific literature at scale, allowing pharmaceutical researchers and scientists to query cause-and-effect relationships across millions of published papers and clinical documents. The platform used a specialised natural language processing system trained to identify causal assertions in biomedical text, producing a structured knowledge graph of disease mechanisms, drug targets, and biological pathways.\n\nThe company was founded in London in 2018 and was acquired by Elsevier, the academic publishing giant, in 2022. The acquisition gave Elsevier an AI layer to sit atop its vast corpus of scientific publications, enabling researchers using ScienceDirect and other Elsevier products to query causal biological knowledge rather than simply searching for documents. Prior to acquisition, Causaly had built a client base among pharmaceutical R&D teams seeking to accelerate literature review and hypothesis generation.\n\nCausaly represented a niche but strategically important segment of the biomedical AI market: causal reasoning and knowledge graph construction. Its acquisition by Elsevier followed a broader trend of academic publishers acquiring AI startups to enhance their platforms, similar to Wiley acquiring Atypon and Springer Nature building AI discovery tools. The company is now integrated into Elsevier Research Intelligence, extending causal AI capabilities to Elsevier institutional subscribers worldwide. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Tempus got there first, launching in 2015 — that's 3 years of extra runway. Causaly didn't arrive until 2018. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Causaly has about 1-50 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Causaly and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.